▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2158 by analyst upside · 2026-09-28
EWTX
Edgewise Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+33.7%
implied upside to consensus target
Current Price $39.34
Consensus Target $52.62
Bull Target $66.0
Bear Target $36.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
8
Hold
2
Sell
0
52-Week Low $14.25
52-Week High $48.51
YTD Return +65.6%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $14.25
52-Week High $48.51
Current Price $39.34
Bear Target $36.0
Bull Target $66.0
● Now $39.34 ● Target $52.62
TRADING DATA
Avg Volume 1.3M
YTD Return +65.6%
Analyst Count 13
Consensus Buy
Upside to Target +33.7%
Last Updated 2026-09-28

ANALYST SUMMARY

Edgewise Therapeutics, Inc. (EWTX) is currently trading at $39.34 with a Wall Street consensus price target of $52.62, implying potential upside of 33.7% over the next 12 months. 13 analysts currently cover EWTX, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $36.0.

EWTX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 65.6% year-to-date and is currently trading near the upper end of its 52-week range of $14.25 – $48.51.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INDV +36.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.8x · Buy
GRFS +47.8%
Grifols, S.A.
$5B · P/E 9.8x · Buy
ACAD +55.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 9.3x · Buy
OPCH +23.9%
Option Care Health, Inc.
$3B · P/E 17.5x · Buy
LIVN +16.3%
LivaNova PLC
$4B · P/E 22.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EWTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-21 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-08-20 43% win rate (7 calls)
Goldman Sachs - Reiterated
Neutral → Neutral 2026-08-11 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-07-20 Building track record
Oppenheimer ● Initiated
Outperform 2026-07-09 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-07-06 62% win rate (8 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-06-17 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-06-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
20/30
Consensus clarity
15/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →